Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05LKP
|
|||
| Former ID |
DAP001238
|
|||
| Drug Name |
Sulfadiazine
|
|||
| Synonyms |
Adiazin; Adiazine; CocoDiazine; Codiazine; Cremodiazine; Cremotres; Debenal; Deltazina; Diazin; Diazolone; Diazovit; Diazyl; Eskadiazine; Liquadiazine; Microsulfon; Neazine; Neotrizine; Palatrize; Piridisir; Pirimal; Pyrimal; Quadetts; Quadramoid; Sanodiazine; Solfadiazina; Spofadrizine; Sterazine; Sulfadiazene; Sulfadiazin; Sulfadiazina; Sulfadiazinum; Sulfanilamidopyrimidine; Sulfapirimidin; Sulfapyrimidin; Sulfapyrimidine; Sulfatryl; Sulfazine; Sulfolex; Sulfonsol; Sulfose; Sulphadiazine; Terfonyl; Theradiazine; Trifonamide; Trisem; Truozine; Honey diazine; Solfadiazina [DCIT]; Sulfapyrimidin [German]; Sulfonamides Duplex; Sulphadiazine E; Triple Sulfas; Zinc Sulfadiazine; A 306; RP 2616; A-306; Coco-Diazine; Lantrisul (TN); Lipo-Diazine; Lipo-Levazine; Metha-Meridiazine; Neotrizine (TN); Pecta-Diazine; RBPI21 & Sulfa; Sulfadiazina [INN-Spanish]; Sulfadiazine (TN); Sulfadiazine, Zinc; Sulfadiazinum [INN-Latin]; Sulfaloid (TN); Sulfonamides Duplex (TN); Sulfose (TN); Terfonyl (TN); Tri-Sulfameth; Triple Sulfa (TN); Triple Sulfas (TN); Triple Sulfoid (TN); Trisulfapyrimidine, oral suspension; A-306 (VAN); CRL-8131 & Sulfadiazine; Di-Azo-Mul; Mixture of sulfadiazine, sulfamerazine, and sulfamethazine; Pecta-diazine, suspension; S. N. 112; S.N. 112; Sulfadiazine [USAN:INN:JAN]; Thi-Di-Mer; N(1)-2-pyrimidinylsulfanilamide; N(1)-2-pyrimidylsulfanilamide; N(sup 1)-2-Pyrimidinylsulfanilamide; N(sup1)-2-Pyrimidinylsulfanilamide; N(sup1)-2-Pyrimidylsulfanilamide; N-(2-Pyrimidinyl)sulfanilamide; Recombinant bactericidal/permeability-increasing protein & Sulfadiazine; Sulfa-Triple #2 (TN); Sulfadiazine (JAN/USP/INN); N1-(Pyrimidin-2-yl)sulfanilamide; Sulfanilamide, N1-2-pyrimidinyl-(8CI); Adiazin, Adiazine, Debenal, Liquadiazine, Microsulfon, Sulfazine, Sulfolex, Sulfadiazine; 2-Sulfanilamido-pyrimidine; 2-Sulfanilamidopyrimidin; 2-Sulfanilamidopyrimidin [German]; 2-Sulfanilamidopyrimidine; 2-Sulfanilylaminopyrimidine; 2-Sulfapyrimidine; 4-AMINO-N-2-PYRIMIDINYLBENZENESULFONAMIDE; 4-Amino-N-(2-pyrimidinyl)benzenesulfonamide; 4-Amino-N-2-pyrimidinyl-benzenesulfonamide; SDZ
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Rheumatic fever [ICD-11: 1B40-1B42; ICD-10: R50] | Approved | [1] | |
| Therapeutic Class |
Antiinfective Agents
|
|||
| Company |
Lilly
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C10H10N4O2S
|
|||
| Canonical SMILES |
C1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N
|
|||
| InChI |
1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)
|
|||
| InChIKey |
SEEPANYCNGTZFQ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 68-35-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9860, 92611, 602777, 642441, 642967, 855872, 933844, 3182910, 4484320, 7847653, 7980699, 8149533, 8153205, 10321441, 10532663, 11112193, 11335718, 11360957, 11363880, 11366442, 11369004, 11372203, 11373882, 11377166, 11461929, 11466051, 11467171, 11485153, 11485742, 11489135, 11491177, 11492157, 11494800, 11533903, 14749834, 24861734, 24899802, 25623038, 26611925, 26679790, 26747022, 26747023, 29224272, 46506164, 47216749, 47440219, 47588965, 47662250, 47736446, 47885378
|
|||
| ChEBI ID |
CHEBI:9328
|
|||
| ADReCS Drug ID | BADD_D02090 | |||
| SuperDrug ATC ID |
J01EC02
|
|||
| SuperDrug CAS ID |
cas=000068359
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
| Studied Microbe: Gut microbiota unspecific | [2], [3] | |||
| Metabolic Reaction | Azo bond reduction | |||
| Resulting Metabolite | 5-aminosalicylic acid | |||
| Metabolic Effect | Increase activity | |||
| Description | Sulfadiazine can be metabolized to 5-aminosalicylic acid by gut microbiota through azo bond reduction, which results in the increase of the drug's activity. | |||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bacterial Dihydropteroate synthetase (Bact folP) | Target Info | Inhibitor | [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Gut microbiome interactions with drug metabolism, efficacy, and toxicity. Transl Res. 2017 Jan;179:204-222. | |||
| REF 3 | Predicting and Understanding the Human Microbiome's Impact on Pharmacology. Trends Pharmacol Sci. 2019 Jul;40(7):495-505. | |||
| REF 4 | Sulfadiazine/hydroxypropyl-beta-cyclodextrin host-guest system: Characterization, phase-solubility and molecular modeling. Bioorg Med Chem. 2008 May 15;16(10):5788-94. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.